Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Stock Slumps 8.13 Percent on Q1 Revenue Shortfall, Net Loss

NEW YORK, May 5 (GenomeWeb News) - Shares in Third Wave Technologies were down 8.13 percent, or $.39, at $4.41 in mid-afternoon trading after the company today reported a sharp downturn in revenues and a net loss for the first quarter of 2005. The stock fell as low as $3.86 early in the day.


As GenomeWeb News reported this morning, Third Wave's revenues for the three months ended March 31 fell to $7.1 million from $15.3 million during the same quarter in 2004. Third Wave attributed the shortfall to a lack of research revenue, a delay by one of its suppliers, and "performance issues" with an instrument from Roche that is required for Third Wave's HCV genotyping analyte-specific reagents.


"As expected, our research revenue will continue to be lower than it has been historically," CEO John Puisis said in a company statement. "We believe the temporary delays that impacted our molecular diagnostic revenue in the first quarter have been remedied."


Research and development costs stayed flat at $2.5 million compared to $2.7 million during last year's first quarter.


Third Wave recorded a net loss of $4.4 million, or $.11 per share, compared to net earnings of $2.8 million, or $.07 per share, during the same quarter last year.


As of March 31, Third Wave had $64.5 million in cash, cash equivalents, and short-term investments.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.